COVID-19 vaccine quarterly surveillance reports (September 2021 to January 2024): COVID-19 vaccine surveillance report: 6 April 2023 (week 14)

Related Organizations

Table of Contents

• COVID-19 vaccine surveillance report 1
• Week 14 1
• 6 April 2023 1
• Contents 2
• Executive summary 3 2
• Vaccine effectiveness 4 2
• Effectiveness against symptomatic disease 4 2
• Effectiveness against hospitalisation 5 2
• Effectiveness of the spring 2022 booster 6 2
• Effectiveness of the autumn 2022 bivalent booster 6 2
• Effectiveness against mortality (vaccines given prior to the autumn 2022 bivalent boosters) 7 2
• Effectiveness against infection 8 2
• Effectiveness against transmission 9 2
• Consensus vaccine effectiveness estimates 10 2
• Effectiveness against BQ.1 11 2
• Effectiveness against XBB.1.5, CH.1.1 and BQ.1 11 2
• Vaccine effectiveness publications 12 2
• Population impact 16 2
• Vaccine coverage 16 2
• Vaccination in pregnancy 16 2
• Vaccine impact on proportion of population with antibodies to COVID-19 23 2
• Seroprevalence 23 2
• Seroprevalence in blood donors aged 17 years and older 24 2
• National prevalence 25 2
• Regional prevalence of infection over time 27 2
• Prevalence by age group 29 2
• Roche S levels by age group and month 30 2
• SARI-Watch surveillance data 33 2
• Vaccination status by time of admission by age group 33 2
• Rate of hospitalisation for COVID-19 in vaccinated people by time since vaccination (any dose) and age group 34 2
• References 38 2
• Executive summary 3
• Vaccine effectiveness 4
• Effectiveness against symptomatic disease 4
• Effectiveness against hospitalisation 5
• Table 1. Vaccine effectiveness against hospitalisation in those aged 65 years and over. Hospitalisation is defined as a stay of at least 2 days with a respiratory code in the primary diagnosis field 5
• Effectiveness of the spring 2022 booster 6
• Table 2. Vaccine effectiveness against hospitalisation for fourth doses, estimated using those 25 to 39 weeks post their third dose as the baseline group 6
• Effectiveness of the autumn 2022 bivalent booster 6
• Table 3. Vaccine effectiveness of the bivalent booster vaccines against hospitalisation in those aged 50 years and older (VE = vaccine effectiveness, CI = confidence intervals) 7
• Effectiveness against mortality (vaccines given prior to the autumn 2022 bivalent boosters) 7
• Table 4. Vaccine effectiveness against mortality in those aged 65 years and older (all vaccine brands combined) (VE = vaccine effectiveness, CI = confidence intervals) 8
• Effectiveness against infection 8
• Effectiveness against transmission 9
• Consensus vaccine effectiveness estimates 10
• Table 5. Consensus estimates of relative vaccine effectiveness against BA.4, BA.5, BQ.1 and CH1.1 Omicron for a booster dose of COVID-19 vaccine compared to 6+ months since the last dose (at least 2 doses) 10
• Effectiveness against BQ.1 11
• Table 6. VE estimates against hospitalisation with BQ.1 and BA.5 for the bivalent boosters in those aged 50 years and older 11
• Effectiveness against XBB.1.5, CH.1.1 and BQ.1 11
• Table 7. VE estimates against hospitalisation with XBB.1.5, CH.1.1 and BQ.1 for the bivalent boosters in those aged 50 years and older 12
• Vaccine effectiveness publications 12
• Table 8. UKHSA publications on the effectiveness of COVID-19 vaccination 12
• Population impact 16
• Vaccine coverage 16
• Vaccination in pregnancy 16
• Vaccine coverage 18
• Figure 1. Women who gave birth and had received COVID-19 vaccine whilst pregnant or pre-pregnancy by month of delivery and by dose number administered 19
• Table 9. Vaccine coverage in women giving birth from September 2022 (when the autumn boost was first offered), by month of delivery0F 20
• Methods 20
• Interpretation and limitations 22
• Main findings 23
• Vaccine impact on proportion of population with antibodies to COVID-19 23
• Seroprevalence 23
• Seroprevalence in blood donors aged 17 years and older 24
• National prevalence 25
• Figure 2. Overall, 12-weekly rolling SARS-CoV-2 antibody seroprevalence (% seropositive) in blood donors 26
• Regional prevalence of infection over time 27
• Figure 3. 12-weekly rolling SARS-CoV-2 antibody seroprevalence (% seropositive) in blood donors by region, using Roche N test; error bars show 95% confidence intervals 27
• Table 10. Roche N seropositivity (95%CI) estimates by NHS region 28
• Prevalence by age group 29
• Figure 4. Population weighted 12-weekly rolling SARS-CoV-2 antibody seroprevalence (% seropositive) in blood donors from the Roche N assay by age group 29
• Table 11. Roche N seropositivity (95%CI) estimates by age group 30
• Roche S levels by age group and month 30
• Figure 5. Categorised Roche S antibody levels by age group and month in N negative samples, April 2022 to March 2023 32
• Figure 6. Categorised Roche S antibody levels by age group and month in N positive samples, April 2022 to March 2023 32
• SARI-Watch surveillance data 33
• Vaccination status by time of admission by age group 33
• Table 12. Vaccination status at time of admission by age group for admissions from 1 September 2022 to 26 March 2023, sentinel data, England 34
• Rate of hospitalisation for COVID-19 in vaccinated people by time since vaccination (any dose) and age group 34
• Figure 7. Estimated rate of hospitalisation for COVID-19 per 100,000 vaccinated people by time since last vaccination (any dose) and age group, admissions from 27 February 2023 to 26 March 2023 inclusive (ISO weeks 9 to 12 2023), England 37
• References 38
• About the UK Health Security Agency 41